Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...
Scientists studied two complement components that are important parts of the immune system and are linked to schizophrenia and autoimmune disorders. They studied the link between two protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback